Mark Schoenberg - 26 Oct 2021 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role: Chief Medical Officer
Signature: /s/ Jason Smith, Attorney-in-Fact
Issuer symbol: URGN
Transactions as of: 26 Oct 2021
Net transactions value: -$1,746
Form type: 4
Filing time: 28 Oct 2021, 14:04:23 UTC
Previous filing: 03 Aug 2021
Next filing: 02 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	URGN	Ordinary Shares	Options Exercise		+208	+0.97%		21,702	26 Oct 2021	Direct	F1
transaction	URGN	Ordinary Shares	Sale	$1,746	-107	-0.49%	$16.32	21,595	27 Oct 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	URGN	Restricted Stock Units	Options Exercise	$0	-208	-50%	$0.000000	209	26 Oct 2021	Ordinary Shares	208		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F2	Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units
F3	The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.